INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO

Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has officially transitioned its CORDStrom™ platform patent application into the U.S. national phase before the USPTO, solidifying its proprietary footprint in the world's largest healthcare market. De-Risked via Favorable PCT Written Opinion: During the international phase, the corresponding Patent Cooperation Treaty (PCT) application received a favorable Written Opinion regarding patentability, significantly validating the novelty, inventiveness, and strength of the underlying asset architecture prior to national entry. Broad Platform-Wide Protection: The application directly targets the Company’s CORDStrom™ mesenchymal stromal cell (MSC) platform, protecting Ebst...